Avanos Medical, Inc. Announces Third Quarter 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy AVNS?
Source: PRnewswire
Financial Performance: Avanos Medical reported a 4.3% increase in net sales to $177.8 million for Q3 2025, but experienced a net loss of $1.4 million compared to a profit of $5.9 million in the same period last year.
Segment Growth: The Specialty Nutrition Systems segment achieved significant growth with net sales of $114.0 million, driven by strong demand in enteral feeding and neonate solutions, while the Pain Management & Recovery segment saw modest growth.
Acquisition and Guidance: The company completed the acquisition of Nexus Medical, enhancing its Specialty Nutrition Systems offerings, and raised its full-year revenue guidance to between $690 million and $700 million.
Challenges and Outlook: Avanos faces challenges from tariffs and a recent goodwill impairment charge of $77 million, but remains optimistic about mitigating these impacts through strategic measures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVNS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVNS
About AVNS
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes TKO, an anti-reflux needleless connector technology, which is used in Neonatal and Pediatric Intensive Care Units. The Pain Management and Recovery portfolio of products includes surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems and Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avanos Medical and Siemens Healthineers Form Strategic Co-Marketing Agreement to Enhance Pain Care Solutions
- Strategic Agreement: Avanos Medical and Siemens Healthineers have entered into a strategic co-marketing agreement aimed at enhancing outpatient and interventional pain care through an integrated ecosystem of imaging and radiofrequency ablation technologies.
- Technological Synergy: This collaboration will equip ambulatory surgery centers, hospitals, and interventional pain practices with complementary technologies that enhance accuracy, efficiency, and consistency in patient care, thereby improving overall healthcare service quality.
- Market Focus: The agreement will initially target the U.S. market, with both companies collaborating on education, sales training, and joint marketing initiatives to increase awareness of the combined solution's clinical and operational benefits.
- Commitment to Value: Avanos CEO Dave Pacitti emphasized that this partnership not only combines RFA expertise with leading imaging technology but also aims to help providers improve procedural precision and expand access to advanced pain management solutions.
See More
Avanos Medical and Siemens Healthineers Form Strategic Partnership to Enhance Pain Management Technologies
- Strategic Partnership: Avanos Medical and Siemens Healthineers have entered into a strategic co-marketing agreement aimed at enhancing outpatient and interventional pain management through an integrated ecosystem of imaging and radiofrequency ablation technologies.
- Market Demand Response: As more pain management procedures shift to outpatient settings, the companies will provide efficient, cost-effective systems to ambulatory surgery centers, hospitals, and interventional pain practices, streamlining workflows and improving clinical outcomes.
- Technological Integration Benefits: The combination of Siemens Healthineers' mobile C-arm systems with Avanos' radiofrequency ablation technology enhances accuracy and consistency across procedures, supporting smoother operations and better patient outcomes.
- Education and Marketing Initiatives: The co-marketing agreement will initially focus on the U.S. market, with both companies collaborating on education, sales training, and joint marketing initiatives to raise awareness of the clinical and operational benefits of their combined solution.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Avanos Medical CEO to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Appearance: Avanos Medical CEO Dave Pacitti will present at the J.P. Morgan Healthcare Conference on January 13 at 2:15 PM PST in San Francisco, showcasing the company's latest advancements in medical technology, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be available via a live webcast on the Investors section of Avanos Medical's website and archived for later access, ensuring that investors unable to attend in person can still obtain key information, thereby enhancing company transparency and investor trust.
- Company Mission: Avanos Medical focuses on delivering clinically superior medical device solutions to address critical healthcare needs, particularly in providing nutritional support and reducing opioid use, aiming to facilitate faster patient recovery and enhance market competitiveness.
- Global Market Position: Headquartered in Alpharetta, Georgia, Avanos Medical holds leading market positions across multiple product categories, continuously developing and marketing globally recognized brands, demonstrating its strong influence in the medical device industry.
See More
Avanos Medical CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: Avanos Medical CEO Dave Pacitti is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at approximately 2:15 p.m. PST, which is expected to highlight the company's latest advancements in medical technology and enhance investor interest.
- Webcast Availability: The presentation will be available via webcast on the Investors section of Avanos Medical's website and archived for later access, ensuring that investors unable to attend in person can still obtain critical information, thereby enhancing the company's transparency and investor relations.
- Company Background: Avanos Medical focuses on delivering clinically superior medical device solutions to address significant healthcare needs, particularly in providing nutritional support and reducing opioid use, underscoring the strategic importance of the company in the medical technology sector.
- Market Leadership: Avanos Medical holds leading market positions across multiple product categories, continuously developing, manufacturing, and marketing globally recognized brands, indicating its strong competitive edge and long-term growth potential in the medical device industry.
See More
Fresh Strong Sell Stocks for December 17
Stocks Added to Zacks Rank #5: Avanos Medical, Archer-Daniels-Midland, and Bank OZK have been added to the Zacks Rank #5 (Strong Sell) List due to downward revisions in their earnings estimates over the past 60 days.
Earnings Estimate Revisions: Avanos Medical's earnings estimate was revised down by 3.3%, Archer-Daniels-Midland by 8.6%, and Bank OZK by 3.4%.
Investment Opportunities: The article highlights that these stocks were selected by Zacks experts as potential high-growth investments, with previous recommendations achieving significant gains.
Access to Recommendations: Readers are encouraged to download a report featuring the "7 Best Stocks for the Next 30 Days" for further investment insights.
See More
Avanos Medical and Siemens Healthineers Form Strategic Co-Marketing Agreement to Enhance Pain Care Solutions
- Strategic Agreement: Avanos Medical and Siemens Healthineers have entered into a strategic co-marketing agreement aimed at enhancing outpatient and interventional pain care through an integrated ecosystem of imaging and radiofrequency ablation technologies.
- Technological Synergy: This collaboration will equip ambulatory surgery centers, hospitals, and interventional pain practices with complementary technologies that enhance accuracy, efficiency, and consistency in patient care, thereby improving overall healthcare service quality.
- Market Focus: The agreement will initially target the U.S. market, with both companies collaborating on education, sales training, and joint marketing initiatives to increase awareness of the combined solution's clinical and operational benefits.
- Commitment to Value: Avanos CEO Dave Pacitti emphasized that this partnership not only combines RFA expertise with leading imaging technology but also aims to help providers improve procedural precision and expand access to advanced pain management solutions.
See More
Avanos Medical and Siemens Healthineers Form Strategic Partnership to Enhance Pain Management Technologies
- Strategic Partnership: Avanos Medical and Siemens Healthineers have entered into a strategic co-marketing agreement aimed at enhancing outpatient and interventional pain management through an integrated ecosystem of imaging and radiofrequency ablation technologies.
- Market Demand Response: As more pain management procedures shift to outpatient settings, the companies will provide efficient, cost-effective systems to ambulatory surgery centers, hospitals, and interventional pain practices, streamlining workflows and improving clinical outcomes.
- Technological Integration Benefits: The combination of Siemens Healthineers' mobile C-arm systems with Avanos' radiofrequency ablation technology enhances accuracy and consistency across procedures, supporting smoother operations and better patient outcomes.
- Education and Marketing Initiatives: The co-marketing agreement will initially focus on the U.S. market, with both companies collaborating on education, sales training, and joint marketing initiatives to raise awareness of the clinical and operational benefits of their combined solution.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Avanos Medical CEO to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Appearance: Avanos Medical CEO Dave Pacitti will present at the J.P. Morgan Healthcare Conference on January 13 at 2:15 PM PST in San Francisco, showcasing the company's latest advancements in medical technology, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be available via a live webcast on the Investors section of Avanos Medical's website and archived for later access, ensuring that investors unable to attend in person can still obtain key information, thereby enhancing company transparency and investor trust.
- Company Mission: Avanos Medical focuses on delivering clinically superior medical device solutions to address critical healthcare needs, particularly in providing nutritional support and reducing opioid use, aiming to facilitate faster patient recovery and enhance market competitiveness.
- Global Market Position: Headquartered in Alpharetta, Georgia, Avanos Medical holds leading market positions across multiple product categories, continuously developing and marketing globally recognized brands, demonstrating its strong influence in the medical device industry.
See More
Avanos Medical CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: Avanos Medical CEO Dave Pacitti is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at approximately 2:15 p.m. PST, which is expected to highlight the company's latest advancements in medical technology and enhance investor interest.
- Webcast Availability: The presentation will be available via webcast on the Investors section of Avanos Medical's website and archived for later access, ensuring that investors unable to attend in person can still obtain critical information, thereby enhancing the company's transparency and investor relations.
- Company Background: Avanos Medical focuses on delivering clinically superior medical device solutions to address significant healthcare needs, particularly in providing nutritional support and reducing opioid use, underscoring the strategic importance of the company in the medical technology sector.
- Market Leadership: Avanos Medical holds leading market positions across multiple product categories, continuously developing, manufacturing, and marketing globally recognized brands, indicating its strong competitive edge and long-term growth potential in the medical device industry.
See More
Fresh Strong Sell Stocks for December 17
Stocks Added to Zacks Rank #5: Avanos Medical, Archer-Daniels-Midland, and Bank OZK have been added to the Zacks Rank #5 (Strong Sell) List due to downward revisions in their earnings estimates over the past 60 days.
Earnings Estimate Revisions: Avanos Medical's earnings estimate was revised down by 3.3%, Archer-Daniels-Midland by 8.6%, and Bank OZK by 3.4%.
Investment Opportunities: The article highlights that these stocks were selected by Zacks experts as potential high-growth investments, with previous recommendations achieving significant gains.
Access to Recommendations: Readers are encouraged to download a report featuring the "7 Best Stocks for the Next 30 Days" for further investment insights.
See More
